Diabetes drugs are Eli Lilly’s bread and butter, but the pharmaceutical giant hasn’t lost its appetite for cancer drugs. It grabbed hold of a few more this week by betting $8 billion on Loxo Oncology. Loxo (NASDAQ: LOXO) has made a name for itself by becoming one of just two companies ever to earn an […]
Original Article: Bio Roundup: #JPM19 Notes, Loxo Buyout, Black Diamond’s Cash & More